Business Daily Media

The Times Real Estate

.

Cellarity signs up with Excelra for GOSTAR database to enrich its drug discovery platform-PR Newswire APAC

  • Written by PR Newswire
Cellarity signs up with Excelra for GOSTAR database to enrich its drug discovery platform-PR Newswire APAC

HYDERABAD, India and CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Excelra[1], a leading global data science & data analytics company, and Cellarity, a flagship pioneering company working on the development of a new generation of medicines to treat diseases at the level of cell behaviours, have today announced an agreement whereby Excelra will provide Cellarity access to its Global Online Structure Activity Relationship database (GOSTAR).

GOSTAR[2] is the world's largest small molecule medicinal chemistry intelligence platform that encompasses over 8 million compounds, linking chemical structure to biological, pharmacological and therapeutic activities. With a vast knowledge base of 28 million SAR data points, GOSTAR equips researchers in the early as well as optimization stages of drug discovery.

Cellarity's drug discovery platform uses high-resolution biological data and unique machine learning capabilities to pioneer an entirely new approach to drug discovery. Cellarity is designing medicines that target and change cell behaviors to unlock treatments in a large number of disease areas. "We are looking forward to using high quality annotated GOSTAR data on millions of small molecules, while leveraging Cellarity's proprietary AI/ML modules to generate predictable drug-like molecules that ultimately guide the design of novel Cell Behavior-Targeted therapies. Our preliminary assessment gives us the confidence in the utility of GOSTAR database," said Ramakanth Sarabu, Head of Chemistry, Cellarity.

"GOSTAR is a widely used structure activity relationship database in AI/ML driven drug discovery programs. We strongly believe that this collaboration equips AI/ML and medicinal chemistry researchers at Cellarity to utilize curated interactions of millions of small molecules with potential drug targets to generate novel compounds with desired pharmacological profiles," said Raveendra Dayam, Director, Chemistry Services, Excelra.

About Cellarity:

Cellarity is a first-of-its-kind therapeutics company that is discovering and developing medicines by studying and altering cell behaviors. Cellarity has developed a powerful, generalizable platform harnessing single-cell technologies, machine learning and proprietary data models of disease to unveil the network state of a given cell. The platform digitizes and quantifies cellular behaviors, unravels the network dynamics that govern those behaviors, and generates medicines that can direct them. https://cellarity.com/[3]

About Excelra:

Excelra's data science and data analytics solutions empower innovation in life sciences. The Excelra Edge comes from a seamless amalgamation of proprietary data assets, domain expertise and data science to accelerate drug discovery & development. Visit www.excelra.com[4]

Contact: Dorothy Paul- Director Marketingdorothy.paul@excelra.com[5] 

 

References

  1. ^ Excelra (www.excelra.com)
  2. ^ GOSTAR (www.excelra.com)
  3. ^ https://cellarity.com/ (cellarity.com)
  4. ^ www.excelra.com (www.excelra.com)
  5. ^ dorothy.paul@excelra.com (www.prnasia.com)

Read more https://www.prnasia.com/story/archive/3179526_AE79526_0

UNSW startup accelerator offers $200K to the next generation of Australian deeptech unicorns

UNSW Founders, Australia’s most recommended startup accelerator, has partnered with fund manager Luminary Partners to invest $200,000 each into 18...

The Future Is Now: AI Modernization Is Reshaping How Business Gets Done

The present business environment imposes stronger requirements on Australian organizations to match the fast-paced digital-first economy requireme...

Businesses losing an average of $493k from data integrity flaws

Managing data responsibly and effectively for the AI age can give organisations a strong competitive advantage, but many are failing to harness th...

AI shopping disruptor Zyft raises $7.5M to lead the next gen of retail tech

Zyft appoints new CEO, Richard Stevens, to lead the latest Waller Group success story, valued at $30 million SYDNEY, 28 April 2025: Zyft, the lea...

Little known law offers savvy Kiwis the opportunity to supercharge their retirement savings

A little-known legal amendment is being leveraged by savvy New Zealanders and expat Brits to supercharge their retirement savings. Not many peop...

Cutting edge AI technology designed for doctors to reduce patient wait times launched in NZ

New Zealand specialist doctors now have access to Artificial Intelligence technology to help reduce patient wait times and experts say it could be...

Sell by LayBy